Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02512965
Other study ID # SC24
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 4, 2016
Est. completion date August 16, 2021

Study information

Verified date August 2021
Source Canadian Cancer Trials Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out if SBRT is better than CRT at controlling pain in the spine 3 months after receiving treatment.


Description:

This research is being done because while there is some evidence suggesting that SBRT may improve treatment for patients with spine metastases, more research is needed to determine if it is better than CRT. The first part of the randomized trial (phase II) looked at whether it was possible (feasible) to provide these treatments in cancer centres across Canada, by aiming to recruit 54 participants within 18 months. This part of the study was successfully completed in early 2017. The second component of this study, called a randomized phase III trial, is now underway. It involves recruiting another 124 participants to receive either CRT or SBRT, using the same study procedure as in the feasibility study. We will continue to obtain information about whether SBRT is better than CRT at controlling pain.


Recruitment information / eligibility

Status Completed
Enrollment 229
Est. completion date August 16, 2021
Est. primary completion date July 21, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologic or cytologic diagnosis of cancer (excluding seminoma, small cell lung cancer and hematologic primaries). - Spinal metastasis documented with MRI and suitable for treatment with radiotherapy with the following characteristics: - Painful, as defined by a pain score = 2 for worst pain in the planned target treatment volume; - = 3 consecutive spinal segments involved by tumour to be included in the planned target volume. The patient may have other spinal metaastases to be treated as per the radiation oncologist's discretion, but the eligible spinal metastatic site has to be one where there is pain and no more than 3 consecutive segments to be included as clinical target volume and appropriate for either 20 Gy in 5 fractions or 24 Gy in 2 fractions per the randomization. - There is no plan to change the pain medication on the first day of protocol treatment with radiotherapy. - ECOG Performance Status 0-2. - Seen by a radiation oncologist and judged to be appropriate for participation in this study including ability to tolerate protocol radiotherapy (SBRT or CRT). - Age of 18 years or older. - Patient is able and willing to complete the Patient Diary (pain and analgesic use). - Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaire in either English or French. The baseline assessment must be completed within required timelines, prior to randomization. Inability (illiteracy in English or French, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible. - Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate. - Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up. - In accordance with CCTG policy, protocol treatment is to begin within 3 weeks of patient randomization. From the time of successful treatment planning, no more than 12 days can elapse before the first fraction of radiotherapy is delivered. - Women/men of childbearing potential must have agreed to use a highly effective contraceptive method. A woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures. - Women of childbearing potential will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation; this may include an ultrasound to rule-out pregnancy if a false-positive is suspected. For example, when beta-human chorionic gonadotropin is high and partner is vasectomized, it may be associated with tumour production of hCG, as seen with some cancers. Patient will be considered eligible if an ultrasound is negative for pregnancy. Exclusion Criteria: - Patients who have a pacemaker, such that MRI cannot be performed or treatment cannot be delivered safely. - Patients with prior treatment with any radionuclide within 30 days prior to randomization. - Patients with prior radiation to the spinal segment intended to be treated with protocol radiotherapy such that the protocol therapy cannot be delivered as intended. - Patients with prior surgery to the spinal segment intended to be treated with protocol radiotherapy. - Patients who have received chemotherapy within 1 week prior to administration of protocol radiotherapy or who are expected/planned to receive chemotherapy within one week of completing protocol radiotherapy. Centre guidelines regarding administration of targeted non-cytotoxic therapy must be followed with the proviso that no systemic anticancer therapy should be administered within 24 hours prior to and post-radiotherapy. Endocrine therapy may be administered during radiotherapy as per the discretion of the treating physician. - Patients with spine instability as judged by a Spinal Instability Neoplastic Score (SINS) of more than 12. - Patients with symptomatic spinal cord compression or cauda equina syndrome resulting from bony compression or epidural compression of the spinal cord and cauda equina, respectively. Symptomatic refers to neurolic deficit in the form of motor, bowel or bladder dysfunction. - Pregnant or lactating women.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
20 Gy in 5 fractions

Conventional SBRT: 24 Gy in 2 fractions


Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide South Australia
Australia Princess Alexandra Hospital Brisbane Queensland
Australia Canberra Hospital Garran
Australia Auckland City Hospital Grafton Aucklund
Australia Royal Brisbane and Womens Hospital Herston
Australia Liverpool Cancer Therapy Centre, Liverpool Hospital Liverpool New South Wales
Australia Peter McCallum Cancer Institute Melbourne Victoria
Australia Peter Mac - Sunshine Hospital St Albans Victoria
Canada Tom Baker Cancer Centre Calgary Alberta
Canada Cross Cancer Institute Edmonton Alberta
Canada Juravinski Cancer Centre at Hamilton Health Sciences Hamilton Ontario
Canada London Regional Cancer Program London Ontario
Canada CHUM-Centre Hospitalier de l'Universite de Montreal Montreal Quebec
Canada Ottawa Hospital Research Institute Ottawa Ontario
Canada BCCA - Centre for the North Prince George British Columbia
Canada CHUQ-Pavillon Hotel-Dieu de Quebec Quebec City Quebec
Canada Centre hospitalier universitaire de Sherbrooke Sherbrooke Quebec
Canada Odette Cancer Centre Toronto Ontario
Canada University Health Network Toronto Ontario
Canada BCCA - Vancouver Cancer Centre Vancouver British Columbia
Canada BCCA - Vancouver Island Cancer Centre Victoria British Columbia
Canada CancerCare Manitoba Winnipeg Manitoba

Sponsors (2)

Lead Sponsor Collaborator
Canadian Cancer Trials Group Trans Tasman Radiation Oncology Group

Countries where clinical trial is conducted

Australia,  Canada, 

References & Publications (1)

Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, Butler J, Chow E, Fehlings MG, Foote M, Gabos Z, Greenspoon J, Kerba M, Lee Y, Liu M, Liu SK, Thibault I, Wong RK, Hum M, Ding K, Parulekar WR; trial investigators. Stereotactic body radi — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Phase III: Complete Pain Response at 3 Months Post-radiation A Complete Pain Response is defined as a pain score of zero (0) at the treated site with no concomitant increase in analgesic intake (stable or reducing analgesics in daily oral morphine equivalent) . 3 months
Secondary Complete Pain Response at 6 Months Post Radiation Based on the International Bone Metastases Consensus Working Party Criteria A Complete Pain Response is defined as a pain score of zero (0) at the treated site with no concomitant increase in analgesic intake (stable or reducing analgesics in daily oral morphine equivalent) . 6 months post radiation
Secondary Radiation Site Progression-free Survival Rate at 6 Months Using MRI Imaging Radiation site progression was defined as:
Gross unequivocal increase in tumor volume or linear dimension > 20%.
Any new or progressive tumor within the epidural space.
Neurologic deterioration attributable to pre-existing epidural disease with equivocal increased epidural disease dimensions on MRI.
6 months.
Secondary Overall Survival Rate at 6 Months Proportion of participants who were alive at 6 months in study. 6 months post radiation
See also
  Status Clinical Trial Phase
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Terminated NCT00593320 - Stereotactic Radiosurgery (SRS) for Spine Metastases N/A
Recruiting NCT05575323 - Randomized Trial on Same-day SBRT and Surgical Stabilization for Symptomatic Spinal Metastases N/A
Completed NCT02987153 - Kypho-Intra Operative Radiation Therapy (IORT) for Localized Spine Metastasis, Phase I/II Study N/A
Recruiting NCT03363685 - Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis
Terminated NCT02407795 - Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases N/A
Completed NCT01365715 - Preoperative Embolization in Surgical Treatment of Spinal Metastases. N/A
Recruiting NCT04863612 - SBRT in the Management of Solid Spinal Metastases
Recruiting NCT04242589 - Trial of Combined Radiotherapy and Vertebroplasty for Patients With Painful Metastatic Spinal Lesions Phase 2
Recruiting NCT01849510 - Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost Phase 2
Not yet recruiting NCT06244264 - The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis N/A
Not yet recruiting NCT06220071 - Multicentric European Study In Patients With Vertebral Metastases
Completed NCT01290562 - Stereotactic Body Radiotherapy (SBRT) for Spinal/Para-Spinal Metastases (Spine SBRT) Phase 2
Recruiting NCT06120426 - En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.
Completed NCT03224650 - Validation of Novel Predictive Score for Patients With Spinal Metastases
Not yet recruiting NCT06093854 - Intraoperative Radiotherapy in Treating Spinal Metastases N/A
Completed NCT02364115 - Randomized Trial Comparing Conventional Radiotherapy With Stereotactic Radiotherapy in Patients With Bone Metastases - VERTICAL Study N/A
Recruiting NCT03398915 - The European Robotic Spinal Instrumentation (EUROSPIN) Study
Not yet recruiting NCT05173467 - Robot-assisted Invasion-controlled Surgery Versus Traditional-open Surgery Against Metastatic Spinal Tumor N/A
Recruiting NCT04248543 - Quantitative MRI for Functional Assessment Following SBRT for Spinal Metastases N/A